OncoCyte (NASDAQ:OCX) Issues Quarterly Earnings Results

OncoCyte (NASDAQ:OCX) announced its quarterly earnings data on Monday. The company reported $0.48 earnings per share (EPS) for the quarter, Zacks reports. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%.

OncoCyte Stock Down 2.1 %

Shares of NASDAQ OCX traded down $0.07 during midday trading on Monday, reaching $3.33. 32,727 shares of the stock traded hands, compared to its average volume of 65,649. The company’s 50 day moving average is $2.68 and its 200 day moving average is $2.72. OncoCyte has a one year low of $1.92 and a one year high of $4.75.

Insider Buying and Selling

In other OncoCyte news, CFO Andrea S. James bought 97,561 shares of OncoCyte stock in a transaction dated Friday, February 7th. The shares were purchased at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the acquisition, the chief financial officer now directly owns 151,231 shares in the company, valued at approximately $310,023.55. This represents a 181.78 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Andrew Arno bought 12,500 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were acquired at an average price of $2.11 per share, for a total transaction of $26,375.00. Following the completion of the transaction, the director now directly owns 81,554 shares in the company, valued at approximately $172,078.94. This represents a 18.10 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 1,288,344 shares of company stock worth $2,649,051. Insiders own 1.58% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of OncoCyte in a research note on Monday, January 13th. They set a “sell” rating for the company.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.